At the healthcare conference, Moderna lowered expected 2025 revenue to the range of $1.5 billion to $2.5 billion -- down from ...
CDC officials say medical professionals are seeing more patients whose illness cannot be traced back to an infected animal or ...
The company's newer product, an RSV ( respiratory syncytial virus) vaccine, has also underperformed, contributing "minimal ...
Is Moderna a no-brainer buy on the sell-off? I wouldn't go that far. Investors should think long and hard about the company's ...
Shares of Moderna tumbled Monday after the vaccine maker predicted a steeper-than-expected sales drop in the new year.
We recently compiled a list of the Jim Cramer Recently Discussed These 15 Stocks & The California Wildfires. In this article, ...
The main reason for this week's decline is that Moderna lowered its 2025 full-year revenue guidance, and by a wide margin.
Moderna's been anything but a high-flying growth stock in this investor's portfolio. So is it high time he gave up on this ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback